Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aksana K Jones

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|January 20, 2019
Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure-Response Analyses Underutilized?Aksana K Jones, Ahmed Hamed Salem, Kevin J Freise
Clinical Pharmacokinetics|November 2, 2020
Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III TrialsAksana K Jones, Eliford Ngaimisi, Mathangi Gopalakrishnan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 20, 2019
Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell TransplantationHechuan Wang, Aksana K Jones, Christopher C Dvorak, et al.
Clinical and Translational Science|July 14, 2025
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2- Metastatic Breast Cancer Data From the Phase 3 TROPiCS-02 TrialAbhishek G Sathe, Aksana K Jones, Paul M Diderichsen, et al.
The AAPS Journal|May 29, 2016
Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic AnalysisAksana K Jones, Kevin J Freise, Suresh K Agarwal, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2016
Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysisKevin J Freise, Martin Dunbar, Aksana K Jones, et al.
Hematological Oncology|December 17, 2016
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergyKevin J Freise, Aksana K Jones, Rajeev M Menon, et al.
Clinical Pharmacokinetics|September 18, 2016
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaKevin J Freise, Aksana K Jones, Doerthe Eckert, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|January 20, 2019
Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure-Response Analyses Underutilized?Aksana K Jones, Ahmed Hamed Salem, Kevin J Freise
Clinical Pharmacokinetics|November 2, 2020
Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III TrialsAksana K Jones, Eliford Ngaimisi, Mathangi Gopalakrishnan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 20, 2019
Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell TransplantationHechuan Wang, Aksana K Jones, Christopher C Dvorak, et al.
Clinical and Translational Science|July 14, 2025
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2- Metastatic Breast Cancer Data From the Phase 3 TROPiCS-02 TrialAbhishek G Sathe, Aksana K Jones, Paul M Diderichsen, et al.
The AAPS Journal|May 29, 2016
Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic AnalysisAksana K Jones, Kevin J Freise, Suresh K Agarwal, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2016
Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysisKevin J Freise, Martin Dunbar, Aksana K Jones, et al.
Hematological Oncology|December 17, 2016
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergyKevin J Freise, Aksana K Jones, Rajeev M Menon, et al.
Clinical Pharmacokinetics|September 18, 2016
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaKevin J Freise, Aksana K Jones, Doerthe Eckert, et al.
Pageof 1